Inspection Record

Eli Lilly and Company — FDA 483 Findings

US FDAInspected 2015-07-11Published 2024-01-17 33 findingsAseptic processing and sterility assuranceComputer system validationOther quality systemEquipment and facilityProcess validationDeviation, CAPA, and investigationTraining and personnelDocumentation and recordsLaboratory and QC controlsEnvironmental monitoringValidation and qualification

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

SOP #0027777-018 ‘Viable Monitoring of Aseptic Manufacturing Areas” describes the frequency of monitoring, sampling methods, recording and analysis of data.

2Computer system validation

SOP #009138 “GMP Computer Systems and Purchased Automated Systems in Quality Control Laboratories (FDA-Regulated)” establish validation requirements for GMP computer systems.

3Other quality system

There is no record to document that the AHU diagrams or As-build drawings have .

4Other quality system

The firm uses aRE Forge: Tester to determine that the finished product yials, rubber stoppers, and aluminum closures meet the predefined torque specifications.

5Equipment and facility

There is no diagrams or system description for the Pressure Test Equipment that is used to leak test the In addition: .

6Aseptic processing and sterility assurance

There is no established written procedure to describe restrictions to prevent cross ; contamination of other aseptic filling lines and/or products when employees have a lyophilized powder on their aseptic gown attire.

7Process validation

SOP #001-001757 “Process Control System Security” is used as a global document to , describe the guidelines for maintaining the security oftheprocess control systems and related documents for Parenteral Products Operations.

8Deviation, CAPA, and investigation

The 1999 and 2000 Deviation Audit Reports do not document the reasons why the .

9Training and personnel

There are a number of ceiling panels above the personnel corridors that are adjacent to oo _ the manufacturing rooms that appeared to be either ajar or positioned in a manner which provide for small openings in the ceiling.

10Aseptic processing and sterility assurance

In the event that aseptic fill room operators leave the filling areas they are required to re-gown into the appropriate clean room attire prior to returning to the aseptic filling areas.

11Other quality system

The yellow color shoe covers are required to be don by personzel prior to entering into the manufacturing area pre-gowning room.

12Other quality system

Conceming coor ain 20-25° C incubator that is used to incubate the media .

13Training and personnel

There are a number of non-approved documents or instructions that are used by personnel, for example: a.

14Equipment and facility

Concerning the HEPA filters in the depyrogenationI The HEPA filters in the bot zone are not jntegrity tested on a periodic base in order to assure that the HEPA filters are not compromised.

15Equipment and facility

The Air Handling Unit(AHU) As-Build drawings document specific pre-filter forthe =| air tbat supplies the various xooms and ultimately theHEPA filters.

16Aseptic processing and sterility assurance

The firm’s procedure (or any associated document) for the transfer of“Ready To Use” stoppers sterilization does not contain provisions for requirements of transfer conditions.

17Other quality system

Non-viable particle measurements are taken with the use ofaPParticie Counter.

18Other quality system

There is an inventory logbook that contains a ATCC culture index, Seed Culture List ATCC Lyophilized Cultures in Stock, Department Lyo’s in Stock, and Nitrogen Tank | ; Inventory list.

19Other quality system

The Differential Pressure System (DPS) that is used to monitor the differential air pressures within the manufacturing ateas provide audio and visual alarms ifthere is a .

20Other quality system

There is no established written procedure to describe the set-up of the capper.

21Documentation and records

The media fill batch records do not document the names or initials ofthe aseptic filling operators who actually perform some of the aseptic filling steps.

22Other quality system

SOP “001-00243 ° “Operation of Capping Machine” provide instructions for the .

23Laboratory and QC controls

SOP #001-001754 “Air Pressure Differential Monitoring” instructs that individual critical alarm report suzomary will be reviewed and signed by the building engineer and ; by a Quality Control representative.

24Laboratory and QC controls

Conceming the acceptance ofmedia that is used in the laboratory for various analyses there is no established written procedure to describe the practice that is used to identify and label approved and non-approved media.

25Training and personnel

During a review of the media i io fill; cess operators were observed opening and closing the , zones, by the door bottom and side edges.

26Equipment and facility

The 1999 and 2000 HEPA filter integrity tests for the Isolators document that there a were “no leaks detected”.

27Other quality system

The following observations concern the 12/19/ tocol for Heat Profile of Incubators for the walk-in 30-35° C incubator, room .

28Other quality system

During the recent airflow pattern.

29Aseptic processing and sterility assurance

The aseptic fill operators areallowed toperform the Quality ControlEM sampling,that is, self-sampling of self-monitoring prior to exiting the aseptic filling area.

30Environmental monitoring

The Environmental Monitoring (EM) Program does not include the use of microbial growth media that is optimum for the propagation of yeast or mold contaminates.

31Validation and qualification

There are a number of observations conceming theBE testy Test Isolators He Validation and Qualification documents.

32Other quality system

There is a CAD Standards Manual that describe the various processes that are to be , .

33Training and personnel

Room Ais used by personnel that are required to change from their street clothes and shoes into the requisite blue or white color work “scrub” suits.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Eli Lilly and Company company profile — full history US FDA documents, 2024 Go to Findings search